daunorubicin


Also found in: Dictionary, Acronyms, Wikipedia.
Related to daunorubicin: doxorubicin

daunorubicin

 [daw″no-roo´bĭ-sin]
an antitumor antibiotic of the anthracycline family, produced by a strain of Streptomyces coeruleorubidus and having antimitotic, cytotoxic, and immunosuppressive effects. As the hydrochloride salt it is administered intravenously in the treatment of acute lymphoblastic leukemia and acute myelogenous leukemia. As a liposome-encapsulated preparation of the citrate salt, it is administered intravenously in the treatment of advanced Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS).
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

dau·no·ru·bi·cin

(daw'nō-rū'bi-sin),
An antineoplastic antibiotic of the rhodomycin group, obtained from Streptomyces peucetius.
Farlex Partner Medical Dictionary © Farlex 2012

daunorubicin

Oncology An antineoplastic antibiotic isolated from Streptomyces spp, effective against ALL and AML, and used for other CAs Toxicity Dose-related BM suppression, mucositis, alopecia, severe local reaction with extravasation
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

ru·bid·o·my·cin

(rū-bid'ō-mī'sin)
An antibiotic used as an antineoplastic; similar to doxorubicin in antitumor activity and in exhibiting cumulative cardiotoxicity.
Synonym(s): daunorubicin.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

daunorubicin

An antibiotic drug used in the consolidation phase of the treatment of acute leukaemia. The drug is on the WHO official list. Brand names are Cerubidin and Daunoxome.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

dau·no·ru·bi·cin

(daw'nō-rū'bi-sin)
An anti neoplastic antibiotic of the rhodomycin group, obtained from Streptomyces peucetius.
Medical Dictionary for the Dental Professions © Farlex 2012
References in periodicals archive ?
"Cytosine Arabinoside with Daunorubicin or Adriamycin for Therapy of Acute Myelocytic Leukemia: A CALGB Study." Blood 60 (2): 454-62.
Caption: Figure 7: Effect of EGFR inhibition with canertinib treatment on the sensitivity of MCF-7 and MCF-7(TamR) cells to a 48-hour treatment with (a) paclitaxel and (b) daunorubicin. Cells were subjected to a 48-hour cytotoxic treatment with the addition of (red) 0 [micro]M, (blue) 0.1 [micro]M, or (green) 1 [micro]M canertinib before 4 days recovery in the same medium minus the cytotoxic.
Designed with Jazz's CombiPlex technology, Vyxeos is a unique liposomal formulation that delivers a fixed-ratio of daunorubicin and cytarabine to the bone marrow that has been shown to have synergistic effects at killing leukemia cells in vitro and in animal models.
Oszczapowicz, "A comparison of the stability of doxorubicin and daunorubicin in solid state," Journal of Pharmaceutical and Biomedical Analysis, vol.
Thandavarayan et al., "Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFkappaB p65 mediated inflammation," International Immunopharmacology, vol.
In our preliminary data, compounds 1-4 were evaluated for their potential selective antiproliferative activity against parental gastric (EPG85- 257) and pancreatic (EPP-181) human cancer cells and their drug-resistant counterparts, selected against mitoxantrone (RNOV) or daunorubicin (RDB), respectively, using a proliferation assay (Reis et al., 2015).
Celator's lead product is VYXEOS (also known as CPX-351), a nano-scale liposomal formulation of cytarabine: daunorubicin that has completed a Phase 3 trial for the treatment of acute myeloid leukemia.
Daunorubicin is an anticancer drug with high side effects, including bone marrow repression and heart toxicity, which is widely used for the treatment of ALL.
The combination of gold -- aptamer nanoparticles has been used in this research to carry daunorubicin drug into the target tissue.
Other treatments include local destruction (cryotherapy), topical alitretinoin (9-cis-retinoic acid), intralesional interferon or vinblastine, superficial radiotherapy, liposomal doxorubicin, daunorubicin, or paclitaxel.
It has been most commonly reported after intravenous use of chemotherapeutic agents such as 5-fluorouracil, docetaxel and combinations of methotrexate, cytosine arabinoside, daunorubicin, 6-mercaptopurine, cyclophosphamide, doxorubicin, bleomycin, vinka alkaloids and dacarbazine.